{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-7NVFOFIB/89fe942a-f779-4fcf-aa2a-4a33dc59710f/HTML","dcterms:extent":"48 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-7NVFOFIB/636b95f3-b2f7-43c8-969a-17eebb94b9d8/PDF","dcterms:extent":"164 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-7NVFOFIB/4ff2a858-7557-42fb-906b-58b1e3894288/TEXT","dcterms:extent":"27 KB"}],"edm:TimeSpan":{"@rdf:about":"1992-2025","edm:begin":{"@xml:lang":"en","#text":"1992"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-7NVFOFIB","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S"},{"@xml:lang":"sl","#text":"Radiology and oncology (Ljubljana)"}],"dcterms:issued":"2004","dc:creator":"Farthmann, Juliane","dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:38"},{"@xml:lang":"sl","#text":"9 strani"},{"@xml:lang":"sl","#text":"str. 111-119"}],"dc:identifier":["ISSN:1318-2099","COBISSID:18166745","URN:URN:NBN:SI:doc-7NVFOFIB"],"dc:language":"en","dc:publisher":{"@xml:lang":"sl","#text":"Association of Radiology and Oncology"},"dc:subject":[{"@xml:lang":"sl","#text":"biokemija"},{"@xml:lang":"en","#text":"Breast Neoplasms"},{"@xml:lang":"en","#text":"diagnostika"},{"@xml:lang":"sl","#text":"Dojka, novotvorbe"},{"@xml:lang":"sl","#text":"Jajčnik, novotvorbe"},{"@xml:lang":"en","#text":"Neoplasms"},{"@xml:lang":"sl","#text":"Novotvorbe"},{"@xml:lang":"sl","#text":"onkologija"},{"@xml:lang":"en","#text":"Ovarian Neoplasms"},{"@xml:lang":"sl","#text":"Polimerazna, verižna reakcija"},{"@xml:lang":"en","#text":"Polymerase Chain Reaction"},{"@xml:lang":"sl","#text":"rak (medicina)"},{"@xml:lang":"en","#text":"Rna Splicing"},{"@xml:lang":"en","#text":"Rna, Messenger"},{"@xml:lang":"sl","#text":"RNA, prenašalna"},{"@xml:lang":"sl","#text":"RNA, spajanje"},{"@xml:lang":"en","#text":"tumor"},{"@xml:lang":"en","#text":"Tumor Cells, Cultured"},{"@xml:lang":"sl","#text":"Tumorske celične kulture"},{"@xml:lang":"en","#text":"Urokinase"}],"dcterms:temporal":{"@rdf:resource":"1992-2025"},"dc:title":{"@xml:lang":"sl","#text":"Development of quantitative RT-PCR assays for wild-type urokinase receptor (uPAR-wt) and its splice variant uPAR-del5|"},"dc:description":[{"@xml:lang":"sl","#text":"The receptor for the serine protease urokinase-type plasminogen activator, uPAR (CD 87), plays an important role in tumor cell invasion and metastasis ofsolid malignant tumors. uPAR is a highly glycosylated, glycan lipid-anchoredmembrane protein, consisting of three homologous domains. Each individual domain is encoded by two exons: DI by exons 2+3, Dll by exons 4+5, and Dlll by exons 6+7. Beside the wild-type (wt) uPAR mRNA, two splice variants either lacking exon 5 (uPAR-del5) or both exons 4 and 5 (uPARdel4/5) have been described. Previously, we studied expression of the mRNA variant uPAR-del4/5 and uPAR mRNA encompassing exons 2, 3, and 4 (i.e. uPAR-wt plus uPAR-del5) applying real-time RT-PCR assays for quantification of the mRNA concentration. In the present paper, we established two additional specific, robust and highly sensitive RT-PCR assays, based on the LightCycler technology, to specifically quantify either uPAR-wt or its splice variant, uPARdel5. Expression of uPAR-wt and uPAR-del5 was analyzed in different human malignant cell lines (ovarian cancer cell lines OVMZ-6 and OVMZ-10; breast cancer cell lines MDA-MB 231, MDA-MB 231 BAG, MDA-MB 435, and aMCF-7; brain tumor cell line LN 18) as well as in a set of 174 breast cancer tissue samples. uPAR-del5 mRNA was found to be expressed very frequently at a rather low level (typically less than 1% of uPAR-wt mRNA). In tumor tissue from breast cancer patients, a statistically significant correlation between uPAR-del5 and uPAR-wt mRNA (r = 0.779; P < 0.001) was observed. There was no association between the expression level of either mRNA and clinical parameters such as nodal status, tumor size and grade. In estrogen receptor negative tumors, a significantly higher uPAR-del5 expression was found (P = 0.023). The two developed quantitative RT-PCR assays described here may aid further analysis of the function and clinical relevance of uPAR-wt and one of its splice variants, uPAR-del5, in malig"},{"@xml:lang":"sl","#text":"Receptor serinske proteinaze plazminogenskega aktivatorja urokinaznega tipa, uPAR (CD 87) igra pomembno vlogo v invaziji tumorskih celic in pri metastaziranju čvrstih malignih tumorjev. uPAR je močno glikoziliran membranski protein, vsajen v glikan-lipidne membrane in sestavljen iz treh homolognih domen. Posamezna domena je kodirana z dvema eksonoma: D1 z eksonoma2 + 3, DII z eksonoma 4 + 5 in DIII z eksonoma 6 + 7. Poleg nemutiraneuPAR-wt RNA, sta bili opisani tudi dve izrezovalni različici, ki bodisi nimata eksona 5 (uPAR-de15) bodisi obeh eksonov 4 in 5 (uPAR-de14/5). Predhodno smo z metodo RT-PCR v realnem času za kvantitativno določevanje mRNAkoncentracije proučevali izražanje mRNA različic uPAR-de14/5 in uPAR mRNA,ki vsebujeta eksone 2,3 in 4 (to je nemutirana uPAR-wt in uPAR-de15). V tem prispevku smo dodatno uveljavili dva specifična, robustna in zelo občutljiva testa RTPCR, ki temeljita na tehnologiji Light-Cyler, da bi specifično določevali vsebnosti uPAR-wt in njegovo izrezovalno različico uPAR-de15. Izražanje uPAR-wt in uPAR-de15 je bilo merjeno v različnih človeških malignih celičnih linijah (ovarijskih rakavih celicah OVMZ-6 in OVMZ-10; rakavih celic dojke MDA-MB 231, MDA-MB 231 BAG, MDA-MB 435 in aMCF-7;možganskih celičnih linijah LN18) kakor tudi v zbiru 174 vzorcev tkiva raka dojke. uPAR-del5 mRNA je bila zelo pogosto izražena v razmeroma nizkih vsebnostih (značilno manj kot 1% glede na uPARwt mRNA). V tumorskem tkivu rakavih bolnikov je bila opažena statistično značilna korelacija med uPAR-de15in uPAR-wt mRNA (r=0.779; P > 0.001). Povezave med izražanjem obeh vrst mRNA in kliničnimi parametri, kakor so status bezgavk velikostjo tumorja in gradusa ni bilo. Značilno povišanje uPAR-de15 pa je bilo opaženo v mailgnihtumorjih z negativnim estrogenskim receptorjem. (Izvleček skrajšan pri2000 znakih)"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-7NVFOFIB","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-7NVFOFIB"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-7NVFOFIB/636b95f3-b2f7-43c8-969a-17eebb94b9d8/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Društvo radiologije in onkologije"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-7NVFOFIB/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-7NVFOFIB"}}}}